Abstract:Background: Mineralocorticoid receptor (MR) antagonists are the recommended medical therapy for primary aldosteronism. Whether this recommendation effectively reduces cardiometabolic risk is not well understood. We aimed to investigate the risk of incident cardiovascular events in patients with primary aldosteronism treated with MR antagonists compared with patients with essential hypertension. Methods: We did a cohort study using patients from a research registry from Brigham and Women's Hospital, Massachusetts General Hospital, and their affiliated partner hospitals. We identified patients with primary aldosteronism using International Classification of Disease, 9th and 10th Revision codes, who were assessed between the years 1991-2016 and were at least 18 years of age. We excluded patients who underwent surgical adrenalectomy, had a previous cardiovascular event, were not treated with MR antagonists, or had no follow-up visits after study entry. From the same registry, we identified a population with essential hypertension that was frequency matched by decade of age at study entry. We extracted patient cohort data and collated it into a de-identified database. The primary outcome was an incident cardiovascular event, defined as a composite of incident myocardial infarction or coronary revascularisation, hospital admission with congestive heart failure, or stroke, which was assessed using adjusted Cox regression models. Secondary outcomes were the individual components of the composite cardiovascular outcome, as well as incident atrial fibrillation, incident diabetes, and death. Findings: We identified 602 eligible patients with primary aldosteronism treated with MR antagonists and 41 853 age-matched patients with essential hypertension from the registry. The two groups of patients had comparable cardiovascular risk profiles and blood pressure throughout the study. The incidence of cardiovascular events was higher in patients with primary aldosteronism on MR antagonists than in patients with essential hypertension (56·3 [95% CI 48·8-64·7] vs 26·6 [26·1-27·2] events per 1000 person-years, adjusted hazard ratio 1·91 [95% CI 1·63-2·25]; adjusted 10-year cumulative incidence difference 14·1 [95% CI 10·1-18·0] excess events per 100 people). Patients with primary aldosteronism also had higher adjusted risks for incident mortality (hazard ratio [HR] 1·34 [95% CI 1·06-1·71]), diabetes (1·26 [1·01-1·57]), and atrial fibrillation (1·93 [1·54-2·42]). Compared with essential hypertension, the excess risk for cardiovascular events and mortality was limited to patients with primary aldosteronism whose renin activity remained suppressed (<1 μg/L per h) on MR antagonists (adjusted HR [2·83 [95% CI 2·11-3·80], and 1·79 [1·14-2·80], respectively) whereas patients who were treated with higher MR antagonist doses and had unsuppressed renin (≥1 μg/L per h) had no significant excess risk. Interpretation: The current practice of MR antagonist therapy in primary aldosteronism is associated with significantly higher risk for incident cardiometabolic events and death, independent of blood pressure control, than for patients with essential hypertension. Titration of MR antagonist therapy to raise renin might mitigate this excess risk. Funding: US National Institutes of Health.

Heightened Cardiovascular Risk in Hypertension Associated With Renin‐Independent Aldosteronism Versus Renin‐Dependent Aldosteronism: A Collaborative Study

Stroke Risks in Primary Aldosteronism with Different Treatments: A Systematic Review and Meta-Analysis

Cardiovascular Risk In Primary Aldosteronism A Systematic Review And Meta-Analysis

Cardiovascular Risk in Primary Aldosteronism

Suppressed Renin Status Is a Risk Factor for Cardiocerebrovascular Events in Bilateral Primary Aldosteronism Treated With Mineralocorticoid Receptor Antagonists

Prevalence of and Risk Factors for Primary Aldosteronism among Patients with Resistant Hypertension in China.

Abstract 11389: Circulating Aldosterone is an Independent Risk Marker for Left Main Coronary Artery Disease

A6748 The Effect of Physiological Phenotyping with Plasma Renin and Aldosterone on Uncontrolled Hypertension

Non-Alcoholic Fatty Liver Disease and Hypokalemia in Primary Aldosteronism among Chinese Population.

THE ASSOCIATION BETWEEN LONG-TERM BLOOD PRESSURE MANAGEMENT AND THE DEVELOPMENT OF CHRONIC KIDNEY DISEASES IN PATIENTS WITH PRIMARY ALDOSTERONISM FOLLOWING TREATMENT

Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study

Optimizing the aldosterone-to-renin ratio cut-off for screening primary aldosteronism based on cardiovascular risk: a collaborative study

Prevalence, Subtype Classification, and Outcomes of Treatment of Primary Aldosteronism: A Prospective Study in China

Clinical Characteristics of Primary Aldosteronism Screened from Chinese Patients with Hypertension: the China Primary Aldosteronism Prospective Study.

Concurrent Primary Aldosteronism and Renal Artery Stenosis: An Overlooked Condition Inducing Resistant Hypertension

Assessing the cardiovascular events and clinical Outcomes of COVID-19 on patients with primary aldosteronism: a global analysis of electronic medical records

The association between blood pressure variability and renal damage in patients with primary aldosteronism

Assessment of cardiovascular disease risk by plasma renin activity changes in patients with primary aldosteronism on mineralocorticoid receptor antagonist treatment

Recent progress in unraveling cardiovascular complications associated with primary aldosteronism: a succinct review

Cardiac Effects of Renin-Angiotensin System Inhibitors in Nonproteinuric CKD

Blood Pressure Levels, Cardiovascular Events, and Renal Outcomes in Chronic Kidney Disease Without Antihypertensive Therapy: A Nationwide Population-Based Cohort Study